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OBJECTIVE: Sorafenib is an oral multikinase inhibitor that has been proven effective as a single-agent therapy in
hepatocellular carcinoma, and there is a strong rationale for investigating its use in combination with other agents.
Vitamin K2 is nearly non-toxic to humans and has been shown to inhibit the growth of hepatocellular carcinoma. In
this study, we evaluated the effects of a combination of sorafenib and vitamin K2 on the growth of hepatocellular
carcinoma cells.
METHODS: Flow cytometry, 3-(4,5-dimethyl-2-thiazolyl-2,5-diphenyl-2H-tetrazolium bromide) and nude mouse
xenograft assays were used to examine the effects of sorafenib and vitamin K2 on the growth of hepatocellular
carcinoma cells. Western blotting was used to elucidate the possible mechanisms underlying these effects.
RESULTS: Assays for 3-(4,5-dimethyl-2-thiazolyl-2,5-diphenyl-2H-tetrazolium bromide) revealed a strong synergistic
growth-inhibitory effect between sorafenib and vitamin K2. Flow cytometry showed an increase in cell cycle arrest and
apoptosis after treatment with a combination of these two drugs at low concentrations. Sorafenib-mediated
inhibition of extracellular signal-regulated kinase phosphorylationwas promoted by vitamin K2, and downregulation
of Mcl-1, which is required for sorafenib-induced apoptosis, was observed after combined treatment. Vitamin K2 also
attenuated the downregulation of p21 expression induced by sorafenib, which may represent the mechanism by
which vitamin K2 promotes the inhibitory effects of sorafenib on cell proliferation. Moreover, the combination of
sorafenib and vitamin K2 significantly inhibited the growth of hepatocellular carcinoma xenografts in nude mice.
CONCLUSIONS: Our results determined that combined treatment with sorafenib and vitamin K2 can work
synergistically to inhibit the growth of hepatocellular carcinoma cells. This finding raises the possibility that this
combined treatment strategy might be promising as a new therapy against hepatocellular carcinoma, especially for
patients with poor liver tolerance.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in the world and is the third leading cause of
cancer-related mortality. The incidence of HCC is high in
Asia and in parts of Africa; in developed Western countries,
its incidence is low but is increasing (1-3). Unlike other
tumors, HCC is often diagnosed at late stages; thus, few
possibilities of curative radical treatment can be offered (4).
For HCC patients, medical treatments, including che-
motherapy, chemoembolization, ablation, and proton beam
therapy, remain disappointing. Most patients experience
disease recurrence and exhibit a 5-year relative survival rate
of less than 10% (5). The prognosis for HCC patients after
curative resection is better, but their 5-year survival rate is
only 30 to 50% (5-7). Clearly, there is an urgent need for new
therapies for this aggressive cancer.
Sorafenib (Nexavar, Bayer HealthCare Pharmaceuticals–
Onyx Pharmaceuticals) is an oral multikinase inhibitor that
suppresses tumor growth by acting on tumor cells and cells
of the tumor vasculature (i.e., vascular endothelial cells and
pericytes) (8,9). Based on its proven efficacy and tolerability
in a Phase III randomized control trial, sorafenib has been
approved for HCC worldwide. However, the results of
clinical studies have indicated that treatment with sorafenib
alone provides only minimal survival benefits for patients
with advanced HCC (10). Therefore, the development of
more efficacious combination therapies involving sorafenib
and other agents appears to be an attractive approach for
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providing improved clinical outcomes in the treatment of
HCC. Indeed, previous studies have shown that combina-
tion therapy with sorafenib and certain other drugs can
result in synergistic or additive inhibitory effects on the
growth of HCC cells.
Recent studies have revealed that vitamin K2 (VK2) has
growth-inhibitory effects in a variety of human cancer cells,
including HCC (11-13). In fact, a few small-sized, controlled
clinical trials have reported that oral administration of VK2
reduced the development and recurrence rates of HCC and
resulted in an improvement in the overall survival of
patients (14,15). However, more recently, a larger-scale,
randomized, controlled trial involving 548 patients did not
confirm the efficacy of VK2 in suppressing HCC recurrence
(16), indicating that VK2 alone may not be sufficient to
produce significant clinical effects.
VK2 has been widely used for osteoporosis, and its long-
term safety has been confirmed. Thus, it would be an ideal
adjuvant agent for cancer therapy. Although the precise
mechanism of how VK2 exerts its growth-inhibitory effects
on cancer cells has not yet been determined, several reports
have indicated that combined treatments with VK2 and
certain other drugs, including some cytotoxic drugs, exert
synergistic anti-cancer effects (11,17-19). In this study, we
report that VK2 synergistically enhances the growth inhibi-
tion effects of sorafenib on HCC cells when these two agents
are administered in combination. In addition, we provide
data regarding the potential mechanisms underlying these
effects. These findings provide a foundation for possible
future clinical evaluations of the efficacy of this combined
treatment approach.
MATERIALS AND METHODS
Ethics statement
The experimental protocol was approved by the Insti-
tutional Animal Care and Use Committee at Southwest
Hospital and was in accordance with the guidelines set forth
by the National Institutes of Health Guide for the Care and
Use of Laboratory Animals.
Cell lines
HCC cell lines (HepG2, Hep3B and HuH7) were obtained
from the Institute of Biochemistry and Cell Biology (Shanghai,
China) and were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) medium supplemented with 10% fetal calf
serum. Cells were cultured in an incubator with humidified
air containing 5% CO2 at 37 C˚.
Reagents
Sorafenib was supplied by the Bayer Corporation (West
Haven, CT, USA). Sorafenib was dissolved in 100%
dimethyl sulfoxide (DMSO) and was then diluted with
DMEM to the desired concentration; the final DMSO
concentration for in vitro studies was 0.1%. VK2 was
purchased from Sigma-Aldrich Chemical Company (St.
Louis, MO, USA) and was dissolved in 99.9% ethanol at a
stock concentration of 50 mM. To generate working solu-
tions, VK2 was then diluted to the appropriate concentra-
tions with medium. Reagents were diluted with DMEM to
the desired concentrations; the final DMSO or ethanol
concentration for in vitro studies was 0.1%. DMSO and
ethanol were added to cultures at 0.1% (V/V) as a solvent
control.
MTT assay
Cells were seeded onto 96-well plates at a density of
16104 cells per well. After 24 h in culture, cells were
exposed to sorafenib and VK2 either alone or in combina-
tion at the indicated concentrations. Control cells were
cultured in DMEM containing the corresponding concen-
trations of DMSO and ethanol. After 2-5 days in culture, the
number of viable cells in each well was determined daily
using 3-(4,5-dimethyl-2-thiazolyl-2,5-diphenyl-2H-tetrazo-
lium bromide) (MTT) assays (Sigma-Aldrich Chemical)
according to the manufacturer’s instructions.
Cell cycle analysis
Cells (56105 cells/ml) were cultured in conditioning
medium containing either sorafenib or VK2 alone or both
in combination at the given concentrations in 6-well plates.
Three days later, cells were trypsinized and harvested by
centrifugation. Flow cytometric analyses of the cell cycle
were performed by staining permeabilized cells with
propidium iodide (PI) for DNA content.
Apoptotic analysis
Annexin V-FITC kits were used to measure the amount of
apoptosis induced by sorafenib or VK2. After treatment for
36 h, cells cultured in 6-well plates were harvested, washed
with PBS at 4 C˚ and then resuspended in 100 ml binding
buffer containing 5 ml Annexin V-FITC and 10 ml of PI. After
a 15 min incubation at room temperature while protected
from light, stained cells were analyzed by flow cytometry.
Western blot and immunoprecipitation analysis
After 48 h in culture with sorafenib and VK2 either alone or
in combination, cells were washed twice with ice-cold PBS,
lysed and sonicated in RIPA buffer. The supernatant of the
homogenate was used for protein determination using a BCA
Protein Assay Kit (Pierce, IL, USA) and for electrophoresis.
Samples with equal amounts of total protein were resolved
using 10% or 12% SDS-PAGE, transferred to nitrocellulose
polyvinylidene difluoride membranes (Amersham Pharmacia,
Piscataway, NJ, USA), and probed with primary antibodies.
The antibodies used included ERK, p-ERK, Mcl-1, cleaved
caspase-3, p21, cyclin D1, and b-actin (Santa Cruz Biotech-
nology Inc., CA, USA). Detection and signal visualization were
performed using the appropriate horseradish peroxidase-
conjugated secondary antibodies (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) and enhanced chemiluminescence
reagents (Thermo Scientific, IL, USA).
For immunoprecipitations, 1 mg of each whole-cell lysate
was immunodepleted with antibody for 2 h. To this
antibody complex, either protein A/G agarose or protein
L agarose (Invitrogen Inc., CA, USA) beads were added for
another hour and incubated at 4 C˚ on an end-to-end shaker.
The beads were washed three times with lysis buffer
without protease inhibitors. Finally, 2X Laemmli buffer
was added to the beads, and the samples were boiled prior
to SDS-PAGE analysis.
In vivo growth inhibition assays
EGFP-expressing HepG2 cells (36107 cells) were injected
subcutaneously in two separate sites on the dorsal flanks of
nude mice. Treatments were initiated when tumors reached
an average volume of approximately 0.1 cm3, which was
approximately seven days after cells had been inoculated.
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Mice were randomly divided into four groups (n = 5 animals
per group): control (DMSO and ethanol, 100 ml each),
sorafenib (1.25 mg/kg body weight), VK2 (2 mg/kg body
weight) (19,20) and combined sorafenib plus VK2 treatment.
The drugs were injected intraperitoneally once daily for 18
consecutive days. Serial changes in tumor volume were
estimated every five days after the initiation of treatment.
Tumor volumes were calculated according to the following
formula: tumor volume = (length6width2)/2. Two days
after the last injection, the animals were anesthetized and
imaged using the CRi Maestro imaging system (CRi
Corporation, Woburn, MA, USA).
Statistical analysis
Data are expressed as the mean¡SD. Differences were
compared using one-way ANOVAs followed by LSD t-tests.
All statistical analyses were performed using SPSS 17.0
(SPSS Inc., Chicago, IL, USA). p-values,0.05 were consid-
ered to be statistically significant.
RESULTS
Sorafenib and VK2 synergistically inhibit the
growth of HCC cells
To assess the growth-inhibitory effects of combining
sorafenib with VK2, HepG2 human HCC cells, which have
frequently been used in evaluations of the effects of sorafenib,
were treated with the study agents, either individually or in
combination, and were then examined using MTT assays. At
the concentrations tested, neither sorafenib nor VK2 alone
caused significant growth inhibition compared to vehicle-
treated controls (p.0.05, Figure 1A), but the combination of
these two agents significantly inhibited cell growth com-
pared to either single-agent treatment (p,0.05, Figure 1A).
Several sorafenib concentrations were tested, and the growth
inhibitory activity of each was enhanced by the addition of
VK2 (p,0.05, Figure 1B). Similar results were observed using
the Hep3B and HuH7 human HCC cell lines (Figure 1C).
Sorafenib and VK2 act synergistically to induce cell
cycle arrest and apoptosis in HepG2 cells
Because the combination of sorafenib and VK2 caused
significant reductions in cell growth, the mechanisms
underlying this effect were investigated. First, the effects
of this treatment combination on cell cycle progression were
examined using flow cytometry. The G1/S ratio was used as
an index of G1 arrest. As shown in Figure 2A, combination
treatment of 2.5 mM sorafenib and 1 mM VK2 induced a
significant accumulation of cells in the G0/G1 phase when
compared to control or single-agent treatments (p,0.05). To
evaluate the induction of apoptosis by this combination,
cells were treated with sorafenib and VK2 individually or in
combination and then examined by Annexin V/PI staining
followed by flow cytometry. As shown in Figure 2B, at the
concentrations tested, neither sorafenib nor VK2 elicited
significant apoptosis as a single agent, but the combination
induced apoptosis in 24.9% of the cells (p,0.05).
VK2 promotes sorafenib-mediated inhibition of
ERK phosphorylation and caspase activation
Sorafenib induces growth inhibition and apoptosis in
human HCC cells by inhibiting the RAF/MEK/ERK
signaling pathway. In this study, the activity of the RAF/
MEK/ERK signaling pathway was determined by measur-
ing the levels of ERK phosphorylation by Western blot
analysis of HepG2 cells treated with sorafenib and VK2,
either alone or in combination. Neither sorafenib nor VK2
alone resulted in a significant inhibition of ERK phosphor-
ylation at the low concentrations used, but combinations of
Figure 1 - Combined treatment with sorafenib and VK2 inhibits
HCC cell growth. (A) Growth inhibition of HepG2 cells by
sorafenib, VK2 or the two in combination. (B) The growth-
inhibitory effects of VK2 in addition to various sorafenib
concentrations. (C) Growth inhibition of Hep3B and HuH7 cells
by sorafenib, VK2 or the two in combination. SF: sorafenib. Each
point represents the mean¡SD of three independent experi-
ments. * p,0.05 vs. control or single-agent treatment.
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these two agents at these concentrations caused significant
reductions in phosphorylated ERK levels, but total ERK
levels were unchanged (p,0.05, Figure 3A and 3B). To
further examine the processes of cell death induced by
combined treatment with sorafenib and VK2, we assessed
expression of Mcl-1 and the marker of apoptosis, cleaved
caspase-3. As shown in Figure 3A, combined treatment with
sorafenib and VK2 significantly decreased the expression of
Mcl-1 and resulted in remarkable caspase-3 cleavage. In
contrast, no obvious decrease of Mcl-1 expression or
increase in caspase-3 cleavage could be detected in samples
treated with sorafenib or VK2 alone.
VK2 attenuates the downregulation of p21
expression induced by sorafenib
The p21 protein inhibits the activity of each member of
the cyclin/Cdk family, which is necessary for the transition
from G1 to S phase, and thus functions as a potent inhibitor
of cell cycle progression in both normal and cancer cells (21).
Previous studies have revealed that sorafenib markedly
decreases p21 levels in several human carcinoma cell lines,
including HepG2 and HuH7, and the p21 inhibitory effect of
sorafenib is independent of the RAF/MEK/ERK signaling
pathway (22-25). Given the previous work indicating that
VK2 suppresses the proliferation of HCC (HepG2) cells by
Figure 2 - Induction of cell cycle arrest and apoptosis by the
combination of sorafenib and VK2. (A) Percentages of cell cycle
distribution. (B) Percentages of apoptotic cells. Values represent
the mean¡SD of five independent experiments. * p,0.05 vs.
control or single-agent treatment.
Figure 3 - Western blot analysis of HepG2 cells after combined
treatment with sorafenib and VK2. (A) Sorafenib and VK2
synergistically inhibited the phosphorylation of ERK, and subse-
quently led to Mcl-1 downregulation and caspase-3 cleavage. p-
ERK: phosphorylated ERK. c-caspase-3: cleaved caspase-3. (B) The
levels of p-ERK and ERK were quantitated by densitometry, and
the ratios of these two proteins are displayed. Values represent
the mean¡SD (n = 3). *p,0.05 vs. control or single-agent
treatment. (C) Changes in p21 expression and the levels of cyclin
D1 binding to p21. Representative results from three indepen-
dent experiments with similar results are shown.
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blocking cell cycle progression from G1 to S phase via the
transcriptional induction of p21 (12,26), we sought to
determine if VK2 could attenuate the downregulation of
p21 expression induced by sorafenib, which would be
predicted to prevent the p21-mediated inhibitory effects on
cell cycle progression. As previously reported, exposure to
sorafenib significantly reduced the expression of p21 in
HepG2 cells. However, when VK2 was combined with
sorafenib, the reduction of p21 was largely abrogated.
Consistent with this, VK2 increased the amount of cyclin
D1 associated with p21 in HepG2 cells (as determined
by immunoprecipitation), even when the total expression
of cyclin D1 was reduced upon combined treatment
(Figure 3C).
The combination of sorafenib and VK2 effectively
inhibits HCC growth in vivo
To clarify whether combined treatment with sorafenib
and VK2 effectively inhibits the growth of HCC cells in vivo,
we next examined the effects of this combination in
subcutaneous mouse models using HepG2 cells. As shown
in Figure 4, sorafenib alone at the given dosage could
suppress in vivo tumor growth (tumor size, p,0.05),
whereas VK2 alone inhibited tumor growth only slightly.
However, the combination of sorafenib and VK2 signifi-
cantly inhibited tumor growth (p,0.05, vs. sorafenib alone),
and some tumors were even shown to shrink significantly.
DISCUSSION
Because HCC typically arises as a result of a liver
damaged by cirrhosis, the livers of HCC patients frequently
do not tolerate conventional chemotherapy well. Therefore,
the development of selective and effective novel therapeutic
strategies that are non-toxic or have low toxicity is required
for HCC patients. Sorafenib is a multikinase inhibitor that
targets several serine/threonine and receptor tyrosine
kinases (8,9). The positive results of clinical trials have
now established sorafenib as the first-ever standard sys-
temic therapy for advanced, unresectable HCC. However,
mono-therapy with this agent occasionally offers only
limited survival benefits. Moreover, given that patients
with cirrhotic livers exhibit poor tolerance to this drug, a
large percentage of patients end up having to decrease their
dose or stop taking the drug entirely. Consequently, a
search for novel approaches for using sorafenib in the
treatment of HCC, especially the establishment of effective
combination therapies, is warranted. Vitamin K, including
VK2, is theoretically an ideal combination drug for antic-
ancer therapy. In fact, Wei et al. (19) reported that vitamin
K, including VK2, can enhance sorafenib-mediated HCC cell
growth inhibition in vitro and in vivo. However, in this
study, Wei et al. focused on the synergistic efficiency of
sorafenib and vitamin K1 and only briefly described the
effects of combined treatment with sorafenib and VK2 (19).
In our study, we systematically tested the synergistic effects
of sorafenib and VK2 on HCC cell growth and further
investigated the possible mechanisms underlying these
effects.
Previous studies have revealed that VK2 itself can inhibit
the RAF/MEK/ERK signaling pathway by inhibiting RAS/
RAF activation, thus causing a decrease in the levels of
phosphorylated ERK in several cancer cell lines, including
HCC HuH7 cells (11,13). In this study, low concentrations of
either sorafenib (2.5 mM) or VK2 (1 mM) alone did not
significantly affect the phosphorylation levels of ERK and
did not induce growth inhibition or apoptosis in HCC
HepG2 cells. However, combined treatment with low
concentrations of both sorafenib and VK2 resulted in
significant cell growth inhibition and apoptosis and a
significant reduction in ERK phosphorylation. Therefore,
there appears to be a strong synergistic effect between these
two drugs in inhibiting the RAF/MEK/ERK pathway.
Sorafenib has been shown to induce apoptosis at high
concentrations in several human cancer cell lines by down-
regulating the expression of the anti-apoptotic protein, Mcl-
1 (27,28). Here, we showed that single treatments with
sorafenib or VK2 (at the low concentrations reported here)
do not decrease Mcl-1 levels or induce apoptosis. However,
when the two drugs are administered in combination, the
expression levels of Mcl-1 are greatly decreased; conse-
quently, the apoptosis marker, cleaved caspase-3, becomes
detectable in HCC cells. This result indicates that when VK2
is present, even low concentrations of sorafenib can induce
significant apoptosis. Thus, it is possible that patients
receiving a combination of sorafenib and VK2 may achieve
improved partial responses (PRs) or even stable disease
(SD). The in vivo experiments in this study revealed that
some nude mice bearing HCC xenografts can achieve
significant tumor shrinkage after combined treatment with
sorafenib and VK2, further strengthening this conclusion.
Figure 4 - Inhibition of tumor growth in vivo by the combination
of sorafenib and VK2. (A) Tumor growth curve from nude mice
transplanted with HepG2 cells and treated with sorafenib, VK2
or the two in combination. Each data point represents the mean
tumor volume (in mm3)¡SD of five mice (10 sites) per treatment.
* p,0.05 vs. control; ** p,0.05 vs. treatment with sorafenib
alone. (B) A representative mouse from each group using CRi
imaging is shown.
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p21 is the founding member of the Cip/Kip family of
cyclin-dependent kinase (Cdk) inhibitors. It plays a critical
role in controlling cell cycle progression through its
inhibition of cyclin/Cdk complexes, which are necessary
for the transition from G1 to S phase (21,29,30). Previous
studies have revealed that sorafenib induces cell cycle arrest
in the G1 phase in cancer cells (31,32) through a complicated
mechanism. However, it has been shown that the expression
of p21 is reduced in almost all cancer cells after sorafenib
exposure (22-25). Due to the critical barrier role of p21 in cell
cycle progression, it is very likely that attenuating the
sorafenib-mediated downregulation of p21 expression will
promote the growth-inhibitory effects of sorafenib. Liu W et
al. (12) has reported that VK2 activates the p21 promoter
and elicits an increase in p21 expression. In this study, we
demonstrate that VK2 partially prevents the down-regula-
tion of p21 induced by sorafenib in HCC cells. Cyclin D1 is a
checkpoint for the G1/S transition (33). We also observed
that the levels of cyclin D1 expression are obviously reduced
in HepG2 cells treated with a combination of sorafenib and
VK2. Nonetheless, immunoprecipitation analysis revealed
that the levels of cyclin D1 binding to p21 are greater
following combination treatments than after sorafenib
treatment alone, thus indicating that the rescued p21
expression exerts its growth inhibition activity by directly
binding to cyclin/Cdk complexes (i.e., cyclin D/Cdk4,
cyclin E/Cdk2 and cyclin A/Cdk2) during the G1/S phase
progression.
In conclusion, our results indicate that sorafenib and VK2
can work synergistically to inhibit the growth of HCC cells.
This finding has significant potential for clinical implica-
tions, as it suggests that combination therapy might have
potential for a clinical application that could enable the use
of lower and less toxic doses of sorafenib to achieve a given
level of efficacy, thus improving tolerability and reducing
adverse effects.
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